How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals announced a Final dividend on Monday, September 4th. Investors of record on Tuesday, September 19th will be given a dividend of 0.05 per share on Tuesday, September 19th. This represents a yield of 0.28%. The ex-dividend date is Monday, September 4th. This is an increase from the stock's previous Final dividend of A$0.04. Read our dividend analysis for CUV .

Is Clinuvel Pharmaceuticals a good dividend stock?

Clinuvel Pharmaceuticals (ASX:CUV) pays an annual dividend of A$0.05 per share and currently has a dividend yield of 0.33%. The dividend payout ratio is 8.77%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for CUV .

What other stocks do shareholders of Clinuvel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Zynga (ZNGA) , Worldpay (WP) , VolitionRx (VNRX) , REA Group (REA) , CSL (CSL) , Cochlear (COH) , Afterpay (APT) .

ASX:CUV

Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CUV Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 124,193 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 0.33%
Price Target: N/A

Stock Analysis

Get Clinuvel Pharmaceuticals alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

CUV Stock News Headlines

March 5, 2024 | finance.yahoo.com

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

March 4, 2024 | msn.com

Dr Boreham’s Crucible: Does Clinuvel’s investor value run deeper than just ‘makes Scenesse’?

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 28, 2024 | morningstar.com

Clinuvel Pharmaceuticals Ltd CUV

February 22, 2024 | fool.com.au

Why Clinuvel, Medibank, Sayona Mining, and Tabcorp shares are sinking today

February 22, 2024 | msn.com

Australia stocks higher at close of trade; S&P/ASX 200 up 0.04%

January 3, 2024 | msn.com

Short & Caught: Pilbara Minerals ASX’s most shorted as lithium stocks targeted

December 7, 2023 | fool.com.au

Looking for ASX growth shares to buy? These could rise ~30%

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

September 20, 2023 | fool.com.au

Down 25% in a month, is this ASX 300 company about to sue the UK Government?

September 1, 2023 | fool.com.au

Why the Clinuvel Pharmaceuticals share price crashed 11% lower today

September 1, 2023 | markets.businessinsider.com

Wilsons Sticks to Its Buy Rating for Clinuvel Pharmaceuticals Limited (CLVLF)

May 4, 2023 | markets.businessinsider.com

Clinuvel Pharmaceuticals Limited (CLVLF) Gets a Buy from Wilsons

April 21, 2023 | msn.com

WILSONS Maintains Clinuvel Pharmaceuticals (ASX:CUV) Overweight Recommendation

April 16, 2023 | finance.yahoo.com

Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but individual investors control 54% of the company

April 4, 2023 | markets.businessinsider.com

Wilsons Sticks to Their Buy Rating for Clinuvel Pharmaceuticals Limited (CLVLF)

March 14, 2023 | finance.yahoo.com

Here's Why We Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

February 7, 2023 | reuters.com

CUV.AX - | Stock Price & Latest News | Reuters

February 1, 2023 | finance.yahoo.com

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

January 16, 2023 | finanznachrichten.de

Clinuvel Pharmaceuticals Limited: CLINUVEL Trial Results Show Drug Reduces DNA Damage

November 24, 2022 | finance.yahoo.com

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock Has Fared Decently: Is the Market Following Strong Financials?

November 18, 2022 | afr.com

Clinuvel Pharmaceuticals Limited

November 7, 2022 | finance.yahoo.com

While institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV), individual investors are its largest shareholders with 54% ownership

October 20, 2022 | finance.yahoo.com

Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Is Looking A Bit Stretched At The Moment

August 31, 2022 | fool.com.au

Why did this ASX 200 healthcare share rocket 16% today?

July 27, 2022 | fool.com.au

Why CLINUVEL and these ASX shares have doubled in value in 12 months

July 18, 2022 | fool.com.au

Clinuvel Pharmaceuticals shares higher on strong quarterly sales growth

See More Headlines

Receive CUV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:CUV
CUSIP: N/A
CIK: N/A
Web: www.clinuvel.com
Phone: 61 3 9660 4900
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A$0.57
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $30.15 million
Net Margins: 36.88%
Pretax Margin: N/A
Return on Equity: 18.98%
Return on Assets: 14.71%

Debt

Debt-to-Equity Ratio: 0.60
Current Ratio: 6.86
Quick Ratio: 10.03

Sales & Book Value

Annual Sales: $81.76 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 19.36
Book Value: A$3.61 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 50,130,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.74

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Philippe Jacques Wolgen M.B.A. (Age 61)
M.D., CEO, MD & Director
Comp: $2.78M
Mr. Darren Michael Keamy B.Com. (Age 51)
CPA, CFO & Company Secretary
Comp: $415.08k
Dr. Dennis J. Wright
Chief Scientific Officer
Mr. Lachlan Hay
Director of Global Operations
Mr. Malcolm Bull
Head of Australian Operations & Investor Relations
Dr. Rose Quadbeck-Diel
Senior Vice President of Regulatory Affairs
Dr. Azza Hamila
Head of Quality & Drug Safety

Key Competitors

View All Competitors

Insiders

CUV Stock Analysis - Frequently Asked Questions

How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?: Clinuvel Pharmaceuticals announced a Final dividend on Monday, September 4th. Investors of record on Tuesday, September 19th will be given a dividend of 0.05 per share on Tuesday, September 19th. This represents a yield of 0.28%. The ex-dividend date is Monday, September 4th. This is an increase from the stock's previous Final dividend of A$0.04.
Read our dividend analysis for CUV.
Is Clinuvel Pharmaceuticals a good dividend stock?: Clinuvel Pharmaceuticals (ASX:CUV) pays an annual dividend of A$0.05 per share and currently has a dividend yield of 0.33%. The dividend payout ratio is 8.77%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for CUV.
What other stocks do shareholders of Clinuvel Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Zynga (ZNGA), Worldpay (WP), VolitionRx (VNRX), REA Group (REA), CSL (CSL), Cochlear (COH), Afterpay (APT).

This page (ASX:CUV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis

About Clinuvel Pharmaceuticals

CUV Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

CUV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info